Funding will accelerate company’s work to democratize state-of-the-art AI models trained on a pre-competitive dataset to speed the successful development of life-saving therapies

The rapid rise of AI in drug discovery brings both unprecedented opportunities and complex challenges. From accelerating the development of better therapies to navigating the proliferation of tools and technologies, the path forward requires clarity, precision, and innovation. For small biotech companies, this moment also raises a critical question: how can we stay competitive with limited resources?

Inductive Bio, a leader in leveraging machine learning (ML) to accelerate compound optimization for small molecule drug discovery, announces the publication of the approach and findings from their recent collaboration with Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers.

As artificial intelligence and machine learning continue to reshape the landscape of drug discovery, this panel will tackle one of the field’s most pressing questions: how do we separate real innovation from overpromised potential?

Inductive Bio emerged with $4.3M in a seed funding round co-led by a16z Bio + Health and Lux Capital, with participation from Character, Bessemer Venture Partners, Alleycorp, and others. Inductive's team has deep expertise building innovative ML products and bringing drugs into the clinic.